Immune checkpoint blockade in renal cell carcinoma Review

   


Authors: Rappold, P. M.; Silagy, A. W.; Kotecha, R. R.; Hakimi, A. A.
Review Title: Immune checkpoint blockade in renal cell carcinoma
Abstract: Immune checkpoint blockade (ICB) is the foundation of current first-line therapies in patients with metastatic renal cell carcinoma (mRCC) with the potential for eliciting long-lasting remissions. With the expanding arsenal of ICB-based therapies, biomarkers of response are urgently needed to guide optimal therapeutic selection. We review the data behind ICB therapy in RCC, emerging biomarkers of response, and the evolving role of surgery in patients with mRCC. © 2020 Wiley Periodicals LLC
Keywords: biomarkers; immunotherapy; kidney cancer; cytoreductive nephrectomy
Journal Title: Journal of Surgical Oncology
Volume: 123
Issue: 3
ISSN: 0022-4790
Publisher: Wiley Blackwell  
Date Published: 2021-03-01
Start Page: 739
End Page: 750
Language: English
DOI: 10.1002/jso.26339
PROVIDER: scopus
PUBMED: 33595892
PMCID: PMC8364550
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101029634&doi=10.1002%2fjso.26339&partnerID=40&md5=2e1a94e3eb77b9748dcd53a4dd509847
Notes: Review -- Export Date: 1 March 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Abraham Ari Hakimi
    323 Hakimi
  2. Andrew William Silagy
    33 Silagy
  3. Ritesh Rajesh Kotecha
    91 Kotecha
  4. Phillip Rappold
    8 Rappold
Related MSK Work